StandardStandard

Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation. / Mallucci, C.L.; Jenkinson, M.D.; Conroy, Eliabeth J. et al.
Yn: The Lancet, Cyfrol 394, Rhif 10208, 26.10.2019, t. 1530-1539.

Allbwn ymchwil: Cyfraniad at gyfnodolynErthygladolygiad gan gymheiriaid

HarvardHarvard

Mallucci, CL, Jenkinson, MD, Conroy, EJ, Hartley, JC, Brown, M, Dalton, J, Kearns, T, Moitt, T, Griffiths, MJ, Culeddu, G, Solomon, T, Hughes, D & Gamble, C 2019, 'Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation', The Lancet, cyfrol. 394, rhif 10208, tt. 1530-1539. https://doi.org/10.1016/S0140-6736(19)31603-4

APA

Mallucci, C. L., Jenkinson, M. D., Conroy, E. J., Hartley, J. C., Brown, M., Dalton, J., Kearns, T., Moitt, T., Griffiths, M. J., Culeddu, G., Solomon, T., Hughes, D., & Gamble, C. (2019). Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation. The Lancet, 394(10208), 1530-1539. https://doi.org/10.1016/S0140-6736(19)31603-4

CBE

Mallucci CL, Jenkinson MD, Conroy EJ, Hartley JC, Brown M, Dalton J, Kearns T, Moitt T, Griffiths MJ, Culeddu G, et al. 2019. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation. The Lancet. 394(10208):1530-1539. https://doi.org/10.1016/S0140-6736(19)31603-4

MLA

VancouverVancouver

Mallucci CL, Jenkinson MD, Conroy EJ, Hartley JC, Brown M, Dalton J et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation. The Lancet. 2019 Hyd 26;394(10208):1530-1539. Epub 2019 Medi 12. doi: 10.1016/S0140-6736(19)31603-4

Author

Mallucci, C.L. ; Jenkinson, M.D. ; Conroy, Eliabeth J. et al. / Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation. Yn: The Lancet. 2019 ; Cyfrol 394, Rhif 10208. tt. 1530-1539.

RIS

TY - JOUR

T1 - Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multi-centre, single-blinded, randomised trial and economic evaluation

AU - Mallucci, C.L.

AU - Jenkinson, M.D.

AU - Conroy, Eliabeth J.

AU - Hartley, John C.

AU - Brown, Michaela

AU - Dalton, Joanne

AU - Kearns, Tom

AU - Moitt, Tracey

AU - Griffiths, Michael J.

AU - Culeddu, Giovanna

AU - Solomon, Tom

AU - Hughes, Dyfrig

AU - Gamble, Carol

N1 - Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

PY - 2019/10/26

Y1 - 2019/10/26

N2 - BACKGROUND: Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest neurosurgical procedures worldwide. Infection of the implanted shunt affects up to 15% of these patients, resulting in prolonged hospital treatment, multiple surgeries, and reduced cognition and quality of life. Our aim was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shunts at reducing infection.METHODS: In this parallel, multicentre, single-blind, randomised controlled trial, we included patients with hydrocephalus of any aetiology undergoing insertion of their first ventriculoperitoneal shunt irrespective of age at 21 regional adult and paediatric neurosurgery centres in the UK and Ireland. Patients were randomly assigned (1:1:1 in random permuted blocks of three or six) to receive standard shunts (standard shunt group), antibiotic-impregnated (0·15% clindamycin and 0·054% rifampicin; antibiotic shunt group), or silver-impregnated shunts (silver shunt group) through a randomisation sequence generated by an independent statistician. All patients and investigators who recorded and analysed the data were masked for group assignment, which was only disclosed to the neurosurgical staff at the time of operation. Participants receiving a shunt without evidence of infection at the time of insertion were followed up for at least 6 months and a maximum of 2 years. The primary outcome was time to shunt failure due the infection and was analysed with Fine and Gray survival regression models for competing risk by intention to treat. This trial is registered with ISRCTN 49474281.FINDINGS: Between June 26, 2013, and Oct 9, 2017, we assessed 3505 patients, of whom 1605 aged up to 91 years were randomly assigned to receive either a standard shunt (n=536), an antibiotic-impregnated shunt (n=538), or a silver shunt (n=531). 1594 had a shunt inserted without evidence of infection at the time of insertion (533 in the standard shunt group, 535 in the antibiotic shunt group, and 526 in the silver shunt group) and were followed up for a median of 22 months (IQR 10-24; 53 withdrew from follow-up). 32 (6%) of 533 evaluable patients in the standard shunt group had a shunt revision for infection, compared with 12 (2%) of 535 evaluable patients in the antibiotic shunt group (cause-specific hazard ratio [csHR] 0·38, 97·5% CI 0·18-0·80, p=0·0038) and 31 (6%) of 526 patients in the silver shunt group (0·99, 0·56-1·74, p=0·96). 135 (25%) patients in the standard shunt group, 127 (23%) in the antibiotic shunt group, and 134 (36%) in the silver shunt group had adverse events, which were not life-threatening and were mostly related to valve or catheter function.INTERPRETATION: The BASICS trial provides evidence to support the adoption of antibiotic shunts in UK patients who are having their first ventriculoperitoneal shunt insertion. This practice will benefit patients of all ages by reducing the risk and harm of shunt infection.FUNDING: UK National Institute for Health Research Health Technology Assessment programme.

AB - BACKGROUND: Insertion of a ventriculoperitoneal shunt for hydrocephalus is one of the commonest neurosurgical procedures worldwide. Infection of the implanted shunt affects up to 15% of these patients, resulting in prolonged hospital treatment, multiple surgeries, and reduced cognition and quality of life. Our aim was to determine the clinical and cost-effectiveness of antibiotic (rifampicin and clindamycin) or silver shunts compared with standard shunts at reducing infection.METHODS: In this parallel, multicentre, single-blind, randomised controlled trial, we included patients with hydrocephalus of any aetiology undergoing insertion of their first ventriculoperitoneal shunt irrespective of age at 21 regional adult and paediatric neurosurgery centres in the UK and Ireland. Patients were randomly assigned (1:1:1 in random permuted blocks of three or six) to receive standard shunts (standard shunt group), antibiotic-impregnated (0·15% clindamycin and 0·054% rifampicin; antibiotic shunt group), or silver-impregnated shunts (silver shunt group) through a randomisation sequence generated by an independent statistician. All patients and investigators who recorded and analysed the data were masked for group assignment, which was only disclosed to the neurosurgical staff at the time of operation. Participants receiving a shunt without evidence of infection at the time of insertion were followed up for at least 6 months and a maximum of 2 years. The primary outcome was time to shunt failure due the infection and was analysed with Fine and Gray survival regression models for competing risk by intention to treat. This trial is registered with ISRCTN 49474281.FINDINGS: Between June 26, 2013, and Oct 9, 2017, we assessed 3505 patients, of whom 1605 aged up to 91 years were randomly assigned to receive either a standard shunt (n=536), an antibiotic-impregnated shunt (n=538), or a silver shunt (n=531). 1594 had a shunt inserted without evidence of infection at the time of insertion (533 in the standard shunt group, 535 in the antibiotic shunt group, and 526 in the silver shunt group) and were followed up for a median of 22 months (IQR 10-24; 53 withdrew from follow-up). 32 (6%) of 533 evaluable patients in the standard shunt group had a shunt revision for infection, compared with 12 (2%) of 535 evaluable patients in the antibiotic shunt group (cause-specific hazard ratio [csHR] 0·38, 97·5% CI 0·18-0·80, p=0·0038) and 31 (6%) of 526 patients in the silver shunt group (0·99, 0·56-1·74, p=0·96). 135 (25%) patients in the standard shunt group, 127 (23%) in the antibiotic shunt group, and 134 (36%) in the silver shunt group had adverse events, which were not life-threatening and were mostly related to valve or catheter function.INTERPRETATION: The BASICS trial provides evidence to support the adoption of antibiotic shunts in UK patients who are having their first ventriculoperitoneal shunt insertion. This practice will benefit patients of all ages by reducing the risk and harm of shunt infection.FUNDING: UK National Institute for Health Research Health Technology Assessment programme.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Anti-Bacterial Agents/administration & dosage

KW - Catheter-Related Infections/blood

KW - Child

KW - Child, Preschool

KW - Cost-Benefit Analysis

KW - Drug-Eluting Stents/adverse effects

KW - Female

KW - Humans

KW - Hydrocephalus/surgery

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Middle Aged

KW - Silver/economics

KW - Single-Blind Method

KW - Ventriculoperitoneal Shunt/adverse effects

KW - Young Adult

U2 - 10.1016/S0140-6736(19)31603-4

DO - 10.1016/S0140-6736(19)31603-4

M3 - Article

C2 - 31522843

VL - 394

SP - 1530

EP - 1539

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10208

ER -